SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Northwest Bioth...
September 08 2015 - 10:05PM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has
been commenced in the United States District Court for the District
of Maryland on behalf of purchasers of Northwest Biotherapeutics,
Inc. (NasdaqCM:NWBO) (“Northwest Biotherapeutics” or the “Company”)
securities during the period between March 8, 2013 and August 20,
2015, inclusive (the “Class Period”). Investors who wish to become
proactively involved in the litigation have until October 26, 2015
to seek appointment as lead plaintiff.
Northwest Biotherapeutics is headquartered in Maryland. Brower
Piven is the only firm headquartered in Maryland with a practice
dedicated primarily to shareholder class action litigation.
If you have suffered a loss from investment in Northwest
Biotherapeutics securities purchased on or after March 8, 2013 and
held through the revelation of negative information during and/or
at the end of the Class Period, as described below, and would like
to learn more about this lawsuit and your ability to participate as
a lead plaintiff, without cost or obligation to you, please visit
our website at
http://www.browerpiven.com/currentsecuritiescases.html. You may
also request more information by contacting Brower Piven either by
email at hoffman@browerpiven.com or by telephone at (410) 415-6616.
No class has yet been certified in the above action. Members of the
Class will be represented by the lead plaintiff and counsel chosen
by the lead plaintiff.
If you wish to choose counsel to represent you and the Class,
you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from
investment in Company securities during the Class Period. Brower
Piven also encourages anyone with information regarding the
Company’s conduct during the period in question to contact the
firm, including whistleblowers, former employees, shareholders and
others.
The Complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants’
failure to disclose during the Class Period that the Company’s
claims regarding positive results from its DCVax-Direct Trial were
based on preliminary and unconfirmed trial results that had not
been reviewed or analyzed by the hospitals conducting the trials
and that the Company was the subject of an aggressive stock
promotion campaign which included promoters using fictitious
identities and false credentials, and that German regulators
required additional information to consider whether to allow the
DCVax-L Trial to continue uninterrupted.
According to the Complaint, following: (1) a June 19, 2014
report from, The Street.com that MD Anderson Cancer
Center had issued a stern rebuke to Northwest Bio for promoting,
unjustified claims about results from the ongoing clinical trial of
DCVax-Direct; (2) a July 7, 2014, report published
on SeekingAlpha.com stating that the Company was the
subject of a massive promotional campaign where in some cases,
authors have used fictitious identities and fake credentials when
they are actually paid writers; (3) an August 21, 2015 pre-market
news story revealing that the Company’s Phase 3 DCVax-L brain
cancer treatment clinical trial in Germany was temporarily
suspended; and (4) a Company announcement that same day that new
screening of patient candidates for the trial had been temporarily
suspended while the Company submitted certain information from the
trial for regulatory review, the value of Northwest Biotherapeutics
shares declined significantly.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150908006727/en/
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Apr 2023 to Apr 2024